GlassScriptPhysician profile
Sheela B Bhat
NPI 1598752008
$2,835.17
in general payments reported to CMS, 2019-2025
26 companies · $69.64 in 2025
The $69.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $514 · 2021: $511 · 2022: $443 · 2023: $264 · 2024: $549 · 2025: $69.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.27 | 2020-2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $369.91 | 2019-2025 | |
| Amgen INC. | $328.96 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $307.07 | 2020-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $224.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.68 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $145.79 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.51 | 2020-2024 | Trulance, Xifaxan |
| Abbvie INC. | $116.74 | 2021-2024 | Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $68.31 | 2019 | |
| Mylan Specialty L.P. | $57.84 | 2020-2021 | |
| Exact Sciences Corporation | $52.05 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $46.59 | 2020-2021 | |
| Abbott Laboratories | $35.02 | 2024-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $32.23 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.02 | 2022 | |
| Sanofi Pasteur INC. | $21.16 | 2023 | |
| Bard Peripheral Vascular, INC. | $19.71 | 2021 | |
| Smith+Nephew, INC. | $18.82 | 2025 | Collagenase Santyl |
| Phadia US INC. | $18.05 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.36 | 2022 | |
| Biogen, INC. | $17.30 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.72 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.89 | 2023 | Quviviq |
| Allergan, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheela Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.